Consumer Health Results Roundup: Genomma, Ipsen And Taisho
Executive Summary
Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.
You may also be interested in...
Taisho Wraps BMS Consumer Health Acquisition; iAnthus Nabs CBD For Life; Health & Wellness M&A In Brief
Bristol-Myers Squibb is free to focus on drug development for patients facing serious diseases, with the divestment of its UPSA consumer health business to Taisho now complete. Separately, Harvest One Cannabis and iAnthus Capital Holdings build their capabilities to meet soaring demand for CBD and other cannabis-derived health, wellness and beauty products.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.